Results 31 to 40 of about 181,758 (302)
La Presse Médicale, 2023 Idiopathic pulmonary fibrosis (IPF) is a progressive devastating lung disease with substantial morbidity. It is associated with cough, dyspnea and impaired quality of life. If left untreated, IPF has a median survival of 3 years. IPF affects ∼3 million people worldwide, with increasing incidence in older patients. The current concept of pathogenesis is
Thomas Koudstaal, Marlies S. Wijsenbeek
openaire +2 more sources
Treatment of Idiopathic Pulmonary Fibrosis [PDF]
Cureus, 2021 Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring in adults and limited to the lungs. In the past, treatment was aimed at minimizing inflammation and slowing the progression of inflammation to fibrosis. However, the underlying lesion in IPF may be more fibrotic than inflammatory,
Gregory Becker +2 more
openaire +3 more sources
TGF-β1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review)
International Journal of Molecular Medicine, 2021 Idiopathic pulmonary fibrosis (IPF) is a worldwide disease characterized by the chronic and irreversible decline of lung function. Currently, there is no drug to successfully treat the disease except for lung transplantation.
Zhimin Ye, Yongbin Hu
semanticscholar +1 more source
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report [PDF]
, 2016 Immunosuppressive therapy has been-until the recent release of new guidelines on diagnosis and management-the recommended treatment for idiopathic pulmonary fibrosis.
CERRI, Stefania +3 more
core +1 more source
Journal of Medical Case Reports, 2022 Background In patients receiving single lung transplantation for idiopathic pulmonary fibrosis, worsening of fibrosis of the native lung is usually progressive over time, with no significant effects on gas exchange.
Tiphaine Goletto +14 more
doaj +1 more source
Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management. [PDF]
, 2017 Idiopathic pulmonary fibrosis (IPF), a fibrosing interstitial pneumonia of unknown etiology, primarily affects older adults and leads to a progressive decline in lung function and quality of life.
Collard, Harold R, Oldham, Justin M
core +2 more sources
Growth factors in idiopathic pulmonary fibrosis: relative roles [PDF]
, 2001 Treatment of idiopathic pulmonary fibrosis patients has evolved very slowly; the fundamental approach of corticosteroids alone or in combination with other immunosuppressive agents has had little impact on long-term survival.
Allen, JT, Spiteri, MA
core +3 more sources
Is It Idiopathic Pulmonary Fibrosis or Not? [PDF]
The Journal of the American Board of Family
Medicine, 2018 Pulmonary fibrosis is not uncommon. Usual interstitial pneumonitis (UIP)/idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic pulmonary fibrotic diseases and has the worst prognosis with a mean life expectancy of 3.8 years.
Genta Ishikawa +2 more
openaire +3 more sources
Lung Cancer in Pulmonary Fibrosis: Tales of Epithelial Cell Plasticity [PDF]
, 2011 Lung epithelial cells exhibit a high degree of plasticity. Alterations to lung epithelial cell function are critically involved in several chronic lung diseases such as pulmonary fibrosis.
Adamson IY +66 more
core +1 more source
Multiscale modelling of reversed Potts shunt as a potential palliative treatment for suprasystemic idiopathic pulmonary artery hypertension in children [PDF]
Biomechanics and Modeling in Mechanobiology (2022), 2021 Reversed Potts shunt (PS) was suggested as palliation for patients with suprasystemic pulmonary arterial hypertension (PAH) and right ventricular (RV) failure. PS, however, can result in poorly understood mortality. Here, a patient-specific geometrical multiscale model of PAH physiology and PS is developed for a paediatric PAH patient with stent-based ...
arxiv +1 more source